2023年6月9日

量子療法——民營生物製藥公司開創性的靶向療法治療RAS-driven癌症——最近宣布D係列融資5070萬美元。資金是由活動性夥伴和廣達電腦現有的投資者支持包括Sofinnova投資,維達,測量員資本(Citadel公司),經度,BVF夥伴和AbbVie企業。其他新參與者GC&H投資(地中海LLP的合夥人基金)和WS投資公司(Wilson Sonsini風險部門)。D係列融資帶來總量自《盜夢空間》提高到超過1.42億美元。利用獨特的喀斯特化學目標多種構象,量子療法”的變構方法有潛力擴大治療範圍KRAS-mutant癌症而逃避已知的耐藥機製。和所得資金將被用於量子的管道包括:兩個化學截然不同的變構喀斯特抑製劑,QTX3034, multi-KRAS抑製劑,和G12D-selective QTX3046喀斯特抑製劑。和兩個項目的數據,最近發表在美國癌症研究協會(AACR)的年度會議上,展示了良好的臨床資料,包括與口服生物利用度和強力的抗腫瘤活性的大腦滲透。這些項目目前正在臨床試驗新藥申請(印第安納州)使研究支持預期的臨床試驗啟動KRAS-driven固體腫瘤跡象在2024年。小說RAF1發現程序采用的直接變構調節活躍RAS-RAF1選擇性膜信號複雜目標廣泛的RAS-driven腫瘤,潛在kinase-independent合成殺傷力。和廣達電腦的口腔小分子領導候選人從這個程序顯示體內概念驗證活動。 KEY QUOTES: “We are pleased to add Avidity Partners to our strong syndicate of high quality investors that share our vision for developing next-generation oral KRAS inhibitors with the potential to address mutations beyond G12C. With this additional funding, we will be well positioned to rapidly advance our two lead KRAS programs into the clinic in 2024 and generate proof-of-concept data.” — Perry Nisen, MD, PhD, Chief Executive Officer of Quanta Therapeutics “Quanta Therapeutics’ team of industry-leading scientists and advisors have developed differentiated platform capabilities and made tremendous strides in drugging one of the most challenging targets in oncology. We are thrilled to lead the Series D investment and look forward to working with the Quanta team to bring these important medicines to cancer patients as quickly as possible.” — Lei Meng, Senior Therapeutics Analyst at Avidity Partners “We are excited about the Quanta team’s potential to apply their unique allosteric-based approach to the development of oral small molecules for patients with difficult-to-treat KRAS-driven cancers. In the current biotech market, I believe companies who are leading their field with differentiated science and continue to show successful execution will garner strong investor support. In my opinion, Quanta is one of those companies.” — Maha Katabi, Ph.D., CFA, General Partner at Sofinnova Investments Trending on Pulse 2.0